Press Releases

TriLink announced that it has entered into a distribution agreement with Sigma-Aldrich to sell its CleanAmp™ dNTPs globally. (more)

Waltham, Mass. – December 7, 2011 – Syndax Pharmaceuticals, Inc. announced today that, with a 23-month patient follow up of ENCORE 301, a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of exemestane with and without entinostat in 130 patients with locally recurrent or metastatic estrogen receptor-positive breast cancer, the median overall survival of exemestane plus entinostat patients reached 26.9 months versus 19.8 months for exemestane plus placebo. This represents a 42% reduction (p=0.04) in the risk of dying for these patients. Previously presented data from ENCORE 301 demonstrated a near doubling in the progression-free survival (PFS) (4.3 vs. 2.3 months) with exemestane plus entinostat and the identification of a subset of these patients whose median PFS reached 8.5 months. (more)

bioteXcel expands rapidly by taking on world leading consultants to their global team. Elisabetta Fineschi the head of bioteXcel consulting has expanded her team to include some of the world’s leading biotech consultants spanning China, India, Europe, US and Canada. Elisabetta is now planning to attend the Genesis 2011 conference in London to partner with relevant companies. (more)

TriLink announced that they have formed a team that will participate in this fall’s Light The Night® Walk, raising money to find cures for cancer and provide critical support to patients and their families. (more)